AstraZeneca’s Brennan to Retire; Lowth Named Interim CEO

AstraZeneca Plc Chief Executive Officer David Brennan will retire from his post, ending a six-year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.